JP2022502010A5 - - Google Patents

Info

Publication number
JP2022502010A5
JP2022502010A5 JP2021512587A JP2021512587A JP2022502010A5 JP 2022502010 A5 JP2022502010 A5 JP 2022502010A5 JP 2021512587 A JP2021512587 A JP 2021512587A JP 2021512587 A JP2021512587 A JP 2021512587A JP 2022502010 A5 JP2022502010 A5 JP 2022502010A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
determination region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021512587A
Other languages
English (en)
Japanese (ja)
Other versions
JP7519990B2 (ja
JP2022502010A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/038138 external-priority patent/WO2020067419A1/en
Publication of JP2022502010A publication Critical patent/JP2022502010A/ja
Publication of JP2022502010A5 publication Critical patent/JP2022502010A5/ja
Priority to JP2024083730A priority Critical patent/JP7777183B2/ja
Application granted granted Critical
Publication of JP7519990B2 publication Critical patent/JP7519990B2/ja
Priority to JP2025194883A priority patent/JP2026021604A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021512587A 2018-09-28 2019-09-27 Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子 Active JP7519990B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024083730A JP7777183B2 (ja) 2018-09-28 2024-05-23 Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子
JP2025194883A JP2026021604A (ja) 2018-09-28 2025-11-14 Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018185120 2018-09-28
JP2018185120 2018-09-28
JP2019104308 2019-06-04
JP2019104308 2019-06-04
PCT/JP2019/038138 WO2020067419A1 (en) 2018-09-28 2019-09-27 Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083730A Division JP7777183B2 (ja) 2018-09-28 2024-05-23 Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子

Publications (3)

Publication Number Publication Date
JP2022502010A JP2022502010A (ja) 2022-01-11
JP2022502010A5 true JP2022502010A5 (cg-RX-API-DMAC7.html) 2022-09-13
JP7519990B2 JP7519990B2 (ja) 2024-07-22

Family

ID=69950671

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021512587A Active JP7519990B2 (ja) 2018-09-28 2019-09-27 Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子
JP2024083730A Active JP7777183B2 (ja) 2018-09-28 2024-05-23 Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子
JP2025194883A Pending JP2026021604A (ja) 2018-09-28 2025-11-14 Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024083730A Active JP7777183B2 (ja) 2018-09-28 2024-05-23 Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子
JP2025194883A Pending JP2026021604A (ja) 2018-09-28 2025-11-14 Cd3およびcd137に結合することができるが、同時には結合しない、抗原結合分子

Country Status (19)

Country Link
US (1) US20210388087A1 (cg-RX-API-DMAC7.html)
EP (1) EP3856785A4 (cg-RX-API-DMAC7.html)
JP (3) JP7519990B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210068079A (cg-RX-API-DMAC7.html)
CN (1) CN113166247A (cg-RX-API-DMAC7.html)
AU (1) AU2019347412A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021005722A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114154A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000739A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005528A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210199A (cg-RX-API-DMAC7.html)
IL (1) IL281787A (cg-RX-API-DMAC7.html)
MA (1) MA53742A (cg-RX-API-DMAC7.html)
MX (1) MX2021003608A (cg-RX-API-DMAC7.html)
PE (1) PE20211072A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550662A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101912UA (cg-RX-API-DMAC7.html)
TW (1) TW202028238A (cg-RX-API-DMAC7.html)
WO (1) WO2020067419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
US12435137B2 (en) 2018-08-03 2025-10-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
JP2022501325A (ja) 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
JP7359864B2 (ja) 2019-07-10 2023-10-11 中外製薬株式会社 クローディン6結合分子およびその使用
JP7736688B2 (ja) * 2020-03-31 2025-09-09 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
AR121692A1 (es) * 2020-03-31 2022-06-29 Chugai Pharmaceutical Co Ltd Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
JP7470760B2 (ja) * 2021-09-29 2024-04-18 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
JP7557922B2 (ja) 2021-09-29 2024-09-30 中外製薬株式会社 Dll3標的多重特異性抗原結合分子の使用
JPWO2023053282A1 (cg-RX-API-DMAC7.html) * 2021-09-29 2023-04-06
WO2023053272A1 (en) * 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
EP4524248A4 (en) * 2022-05-12 2026-07-01 Astellas Pharma Inc MULTISPECIFIC ANTI-TAA AND ANTI-CD3 ANTIBODY
WO2024114676A1 (zh) * 2022-11-29 2024-06-06 江苏恒瑞医药股份有限公司 Cldn18.2/4-1bb结合蛋白及其医药用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
AU1219000A (en) 1998-10-22 2000-05-08 Regents Of The University Of California, The Functionally assembled antigen-specific intact recombinant antibody and a methodfor production thereof
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
WO2006132352A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2を含有する医薬組成物
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
EP2283358B1 (en) 2008-04-29 2015-04-22 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
US20140080153A1 (en) 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
MX2016003617A (es) 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
CA2929044A1 (en) * 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
MX380176B (es) * 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
EP3305322A4 (en) * 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
KR102692708B1 (ko) * 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
JP7357616B2 (ja) * 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子

Similar Documents

Publication Publication Date Title
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
CN110431231B (zh) 抗-cd3抗体和包含所述抗体的分子
IL272274B1 (en) B7-h4 antibodies and methods of use thereof
TW202208423A (zh) Sars-cov-2抗體及其選擇和使用方法
KR20210137477A (ko) 이중기능성 융합 단백질 및 그것의 제약학적 용도
JP7858629B2 (ja) Fgfr3抗体および使用の方法
EP3359565A1 (en) Anti-wt1/hla-specific antibodies
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2020515277A5 (cg-RX-API-DMAC7.html)
JP2023133432A5 (cg-RX-API-DMAC7.html)
CA3210289A1 (en) Mage-a4 peptide-mhc antigen binding proteins
TW201134489A (en) Basigin binding proteins
JP2023542209A5 (cg-RX-API-DMAC7.html)
CN115515615A (zh) Pilra抗体及其使用方法
CA3194641A1 (en) Anti-tigit antibody, and pharmaceutical composition and use thereof
KR102882299B1 (ko) 항체 및 사용 방법
EP4637928A1 (en) Antibodies targeting cd45
WO2021258337A1 (en) Human monoclonal antibodies against tigit for immune related diseases
JP2022505144A5 (cg-RX-API-DMAC7.html)
JP2020521752A (ja) グロボhに対するヒト化抗体および癌治療におけるその使用
JP2025537255A (ja) 抗アルファ5インテグリン抗体及びその使用
RU2021110931A (ru) Антигенсвязывающие молекулы, обладающие способностью связываться с cd3 и cd137, но не одновременно
US20240010730A1 (en) Bispecific antibody and use thereof
WO2022211629A1 (en) Novel pd-1 binding domains
WO2022100694A1 (zh) 抗体及其制备方法